Dear Logan8, There has been some question as to what role ovarian ablation (drying up the ovaries) has in the treatment of early stage breast cancers. This treatment has shown benefit in the treatment of metastatic breast cancer, so they are now studying it in terms of adjuvant treatment for early cancers. The reason for doing it would be to further decrease the estrogen available to estrogen-receptive tumors.
The National Institute of Health had a panel of experts review the available data as of December 2000 regarding adjuvant treatment of breast cancer. This panel provided a consensus statement regarding the various aspects of adjuvant therapy for breast cancer. Concerning adjuvant hormone therapy should be offered to women whose tumors express hormone receptor protein (yours does). At present five years of tamoxifen is standard adjuvant hormone therapy; ovarian ablation represents an alternative option for selected premenopausal women.
Ovarian ablation is used far less frequently in the United States. Methods to accomplish ablation are surgical (oopherectomy), radiation therapy to the ovaries, or chemical suppression of ovarian function. Ovarian ablation appears to produce a similar benefit to some chemotherapy regimens. Combining ovarian ablation with chemotherapy has not been shown to provide an additional advantage to date. The value of combining hormonal therapies has not yet been adequately explored.
Side effects to ablation are those experienced with natural menopause. In your search for additional reading material regarding ovarian ablation you could look in terms of the different methods. Oopherectomy (removal of the ovaries) is the name of the surgical procedure. Some names of common medications used to produce ablation are goserelin (also known as Zoladex), or leuprolide (Lupron).